Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents

Ethan A. Natelson, Beppino C. Giovanella, Claire F. Verschraegen, Kim M. Fehir, Peter D. De Ipolyi, Nick Harris, John S. Stehlin

Research output: Contribution to journalArticle

64 Scopus citations

Abstract

Groups of 52 and 29 patients with refractory cancers received either native camptothecin (CPT) or 9-nitrocamptothecin (9NC), respectively, in Phase I clinical trials designed to determine the maximum tolerated dose, toxicity and potential efficacy of orally administered camptothecins. Favorable responses occurred with both compounds (11% after CPT, 24% after 9NC). Although both agents could be taken safely for extended periods, dose limiting toxicities were substantial. Diarrhea was the major clinical problem with CPT, and myelosuppression with 9NC. Both compounds could cause hemorrhagic cystitis. The antitumor activity demonstrated suggests that further investigation of orally administered camptothecin analogs is warranted.

Original languageEnglish (US)
Pages (from-to)224-230
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume803
DOIs
StatePublished - 1996

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Fingerprint Dive into the research topics of 'Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents'. Together they form a unique fingerprint.

Cite this